Regulatory reversal boosts investor confidence and puts mRNA flu shot on track for potential approval this year
Moderna (MRNA) has received renewed momentum after the U.S. Food and Drug Administration (FDA) agreed to review its experimental influenza vaccine, reversing a prior decision to reject the company’s initial application. The regulatory shift follows modifications made by Moderna to address the FDA’s earlier concerns, marking a significant step forward for the company’s expanding mRNA vaccine pipeline.
The FDA has accepted Moderna’s revised submission, which seeks full approval for adults aged 50 to 64 and accelerated approval for those aged 65 and older. As part of the agreement, Moderna will conduct a post-marketing study focused on older adults to further evaluate the vaccine’s effectiveness and safety. The FDA is expected to deliver its final decision by August 5, potentially allowing the vaccine to become available later this year.
Investor reaction was swift and positive. Moderna’s shares surged more than 8% in premarket trading following the announcement, reflecting renewed optimism about the company’s growth prospects beyond its COVID-19 vaccine portfolio. The flu vaccine represents a key strategic initiative as Moderna works to diversify its revenue streams and expand the application of its mRNA technology.
The FDA’s earlier rejection had cited concerns about the strength of the vaccine used in the control group for older participants during clinical trials. Moderna’s revised approach addressed these issues, enabling the agency to proceed with its review.
The company’s mRNA technology, which played a central role in combating the COVID-19 pandemic, remains a major focus of its long-term strategy. CEO Stéphane Bancel expressed confidence in the vaccine’s potential, emphasizing the importance of providing seniors with additional protection against seasonal influenza.
If approved, Moderna’s flu vaccine would represent a major milestone, reinforcing the broader potential of mRNA technology in treating infectious diseases. The outcome of the FDA’s review could significantly influence Moderna’s position in the competitive global vaccine market and support its continued innovation in next-generation immunizations.
You might like this article:KULR Technology Partners with Hylio to Develop NDAA-Compliant Drone Battery Systems
